Literature DB >> 33932936

An analysis of tumor-related potential spinal column instability (Spine Instability Neoplastic Scores 7-12) eventually requiring surgery with a 1-year follow-up.

Enrique Vargas1,2, Dennis T Lockney1, Praveen V Mummaneni1, Alexander F Haddad1,2, Joshua Rivera1, Xiao Tan1, Alysha Jamieson1, Yasmine Mahmoudieh1, Sigurd Berven3, Steve E Braunstein4, Dean Chou1.   

Abstract

OBJECTIVE: Within the Spine Instability Neoplastic Score (SINS) classification, tumor-related potential spinal instability (SINS 7-12) may not have a clear treatment approach. The authors aimed to examine the proportion of patients in this indeterminate zone who later required surgical stabilization after initial nonoperative management. By studying this patient population, they sought to determine if a clear SINS cutoff existed whereby the spine is potentially unstable due to a lesion and would be more likely to require stabilization.
METHODS: Records from patients treated at the University of California, San Francisco, for metastatic spine disease from 2005 to 2019 were retrospectively reviewed. Seventy-five patients with tumor-related potential spinal instability (SINS 7-12) who were initially treated nonoperatively were included. All patients had at least a 1-year follow-up with complete medical records. A univariate chi-square test and Student t-test were used to compare categorical and continuous outcomes, respectively, between patients who ultimately underwent surgery and those who did not. A backward likelihood multivariate binary logistic regression model was used to investigate the relationship between clinical characteristics and surgical intervention. Recursive partitioning analysis (RPA) and single-variable logistic regression were performed as a function of SINS.
RESULTS: Seventy-five patients with a total of 292 spinal metastatic sites were included in this study; 26 (34.7%) patients underwent surgical intervention, and 49 (65.3%) did not. There was no difference in age, sex, comorbidities, or lesion location between the groups. However, there were more patients with a SINS of 12 in the surgery group (55.2%) than in the no surgery group (44.8%) (p = 0.003). On multivariate analysis, SINS > 11 (OR 8.09, CI 1.96-33.4, p = 0.004) and Karnofsky Performance Scale (KPS) score < 60 (OR 0.94, CI 0.89-0.98, p = 0.008) were associated with an increased risk of surgery. KPS score was not correlated with SINS (p = 0.4). RPA by each spinal lesion identified an optimal cutoff value of SINS > 10, which were associated with an increased risk of surgical intervention. Patients with a surgical intervention had a higher incidence of complications on multivariable analysis (OR 2.96, CI 1.01-8.71, p = 0.048).
CONCLUSIONS: Patients with a mean SINS of 11 or greater may be at increased risk of mechanical instability requiring surgery after initial nonoperative management. RPA showed that patients with a KPS score of 60 or lower and a SINS of greater than 10 had increased surgery rates.

Entities:  

Keywords:  SINS; Spine Instability Neoplastic Score; tumor

Year:  2021        PMID: 33932936     DOI: 10.3171/2021.2.FOCUS201098

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  2 in total

1.  Impact of Spinal Instrumentation on Neurological Outcome in Patients with Intermediate Spinal Instability Neoplastic Score (SINS).

Authors:  Moritz Lenschow; Maximilian Lenz; Niklas von Spreckelsen; Julian Ossmann; Johanna Meyer; Julia Keßling; Lukas Nadjiri; Sergej Telentschak; Kourosh Zarghooni; Peter Knöll; Moritz Perrech; Eren Celik; Max Scheyerer; Volker Neuschmelting
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

Review 2.  Ten Years After SINS: Role of Surgery and Radiotherapy in the Management of Patients With Vertebral Metastases.

Authors:  Nicolas Serratrice; Joe Faddoul; Bilal Tarabay; Christian Attieh; Moussa A Chalah; Samar S Ayache; Georges N Abi Lahoud
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.